EN DE
Watch Sareum Holdings for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sareum Holdings (SAR) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Sareum Holdings stock £0.09, price £0.15, that is 39.2% below the price, quality 48 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00BMC3RJ87

SH Sareum Holdings logo Thin data Nov 10, 2026

Sareum Holdings

SAR · LSE
Very expensive, weak quality

Our calculation puts a fair price 39% below what the stock costs today.

Low debt
Quality 48/100
Mixed vs. peers (4/8)
Fair value £0.0881 · Strongly overvalued
Weak Growth
Negative free cash flow
Narrow moat 3/100 · thin data
Thin data
Estimate
Watch Sareum Holdings for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£4.58 £0.1025 Fair Value £0.0881 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range £0.1025 – £4.58 · fair‑value band £0.0661 – £0.1101 · the £0.1450 price screens above the £0.0881 fair value. As of Nov 10, 2026.

Follow Sareum in your weekly email

Every Wednesday you see whether Sareum is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases.

Show moreShow less

The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases.

It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms.

The company has strategic collaboration with Receptor.AI launched in August 2025 to accelerate discovery and optimisation of BBB-permeable TYK2/JAK1 inhibitors; and completion of initial stage expected Q4 2025.

Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.

Stock analysis

Sareum Holdings (SAR) currently trades at £0.1450, while our estimate is £0.0881, 39% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: £0.0661 (bear) to £0.1101 (bull), the price of £0.1450 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Sareum Holdings reported revenue of £0 in FY2025 versus £0 in FY2021. Reported net income was −£3.3M in FY2026.

Key figures

Market cap £24.5M Micro · EPS (TTM) £−0.0200 · Return on equity −178% · Return on assets (EBIT) −125% (4-year average) · Revenue (TTM) £47.2K · Free cash flow −£2.6M · Net cash £3.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −39%, SAR screens richer than that median.

Fair Value

Bear £0.0661 Fair Value £0.0881 Bull £0.1101
Price £0.1450 · Downside -39.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 59
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 26
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−561.9% (2004) → −2,382.6% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

SAR screens overvalued: fair value 39% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Sareum Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −39.2% · Below median
Profitability
Return on assets −77.1% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 10.78× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs SAR
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs SAR
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs SAR
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs SAR
argenx SE ARGX $971.55 $908.40 −7% vs SAR
CSL Limited CSL A$201.68 A$181.40 −10% vs SAR
Moderna, Inc MRNA $250.83 $158.70 −37% vs SAR
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs SAR
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs SAR
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs SAR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sareum Holdings: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sareum Holdings Fair Value". https://www.fairvalue-calculator.com/stock/SAR.LSE

Frequently asked questions

Is Sareum Holdings (SAR) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is £0.0881 versus a price of £0.1450, about 39% lower (overvalued).
What is the fair value of SAR?
Our estimate for Sareum Holdings is £0.0881 (as of Nov 10, 2026), built from audited fundamentals. The current price: £0.1450.
What is the quality score of SAR?
Sareum Holdings has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sareum Holdings (SAR)?
Our calculated price target is the estimate of £0.0881 (as of Nov 10, 2026). Cautious scenario £0.0661, optimistic scenario £0.1101. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sareum Holdings stock forecast for 2026?
Our estimate puts fair value at £0.0881, about 39% lower versus a price of £0.1450 (overvalued). Cautious scenario £0.0661, optimistic scenario £0.1101. The calculation is refreshed regularly with new filings.
What is the revenue of Sareum Holdings (SAR)?
Sareum Holdings reported trailing-twelve-month revenue of about £47.2K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Sareum Holdings (SAR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sareum Holdings it is £0.0881 per share (as of Nov 10, 2026), against a price of £0.1450.
Is Sareum Holdings stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SAR trades above its calculated fair value: price £0.1450, fair value £0.0881, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SAR?
No. The price is what the market pays today (£0.1450); the fair value is what the company's own numbers justify (£0.0881). For Sareum Holdings the two are £0.0569 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sareum Holdings worth?
The market values Sareum Holdings at about £24.5M (market capitalisation, as of Nov 10, 2026). Per share that is £0.1450; our models calculate a fair value of £0.0881 per share.
What do the bullish and bearish scenarios say about SAR?
Our models span a range for Sareum Holdings: cautious scenario £0.0661, base £0.0881, optimistic £0.1101 per share (as of Nov 10, 2026, price £0.1450). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sareum Holdings (SAR)?
Balance-sheet figures for Sareum Holdings (as of Nov 10, 2026): return on equity −178.5%, debt of 0.06 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is SAR from its 52-week high?
Sareum Holdings trades at £0.1450, about 61% below its 52-week high of £0.3700 and 21% above the low of £0.1200 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0881 is for.
Which stocks are comparable to Sareum Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sareum Holdings stock attractive at the current price?
The data as of Nov 10, 2026: price £0.1450, calculated fair value £0.0881 (−39%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Sareum Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sareum Holdings (SAR)?
The closing price on Nov 10, 2026 was £0.1450. Our estimate is £0.0881, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sareum Holdings right now?
The price sits above even our optimistic bull case (£0.1101). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Sareum Holdings

How large is the market capitalisation of Sareum Holdings (SAR)?
The market capitalisation of Sareum Holdings is £24.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sareum Holdings (SAR)?
Earnings per share at Sareum Holdings are £−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sareum Holdings (SAR)?
The return on equity (ROE) of Sareum Holdings is −178% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sareum Holdings (SAR)?
On an EBIT basis the return on assets of Sareum Holdings is −125% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Sareum Holdings (SAR) generate?
The free cash flow of Sareum Holdings is −£2.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sareum Holdings (SAR) hold?
Sareum Holdings holds more cash than debt, £3.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sareum Holdings in the live analysis

One click puts Sareum Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.